Search

Astellas Pharma Inc.
  • About
    • Philosophy
    • Vision & Strategy
    • Group Code of Conduct
    • Corporate Information
    • Policies & Position Statements
    • Medical Education
      • Support for Medical Education
      • Congress: Grants to HCOs
    Recommended
    Corporate Information

    Europe is a global centre of excellence in healthcare and Astellas is committed to supporting Europe, the Middle East and Africa (EMEA)…

    Read More
  • Therapy areas
    • ADVAGRAF™
    • BETMIGA ™
    • EVRENZO™
    • MYCAMINE™
    • PROGRAFT™
    • VESICARE™
    • VESOMNI™
    • XOSPATA™
    • XTANDI™
  • Products
  • Innovation
    • R & D
      • Clinical Trials
      • Approach
      • Ethics & Principles
    • Investigator Sponsored Research
    Recommended
    Clinical Trials

    Astellas has established a website to disclose information obtained from Astellas-sponsored clinical trials…

    Read More
  • Sustainability
    • CSR-Based Management
      • ISO26000
      • Materiality
    • CSR Activities in Five Fields
      • Society
      • Environment
      • Employees
      • Ethics & Compliance
    • Access to Health
      • ACTION ON FISTULA™
    • Transparency
    • Modern Slavery Act
    • Global Sustainability Policy
    Recommended
    Access to Health

    Advances continue to be made in technology and medicine that address unmet medical needs. However, there still remain barriers for many people…

    Read More
  • News
    • News
    • Media Contacts
    • Social Media Code of Conduct
    Recommended
    Media Contacts

    The Astellas EMEA Corporate Communications team will respond to calls and emails from journalists…

    Read More

Common header menu

  • CAREERS
  • CONTACT US
  • WORLDWIDE
  • NETHERLANDS
  • WORLDWIDE - NETHERLANDS
  1. Home
  2. Products

Products

Transplantatie

  • ADVAGRAF™
      – Bijsluiter ADVAGRAF™ 0,5, 1, 3 & 5 mg
      – SmPC ADVAGRAF™ 0,5, 1, 3 & 5 mg
     
  • PROGRAFT™
      – Bijsluiter PROGRAFT™-caps
      – Bijsluiter PROGRAFT™-conc
      – SmPC PROGRAFT™-caps
      – SmPC PROGRAFT™-conc
 


Anti-infectiva

  • MYCAMINE™
      – Bijsluiter MYCAMINE™ 50 & 100 mg
      – SmPC MYCAMINE™ 50 & 100 mg

    Additioneel risicominimalisatie materiaal
    Checklist voor voorschrijvers micafungine

Oncologie

  • PADCEV™
      – Bijsluiter PADCEV™ poeder voor concentraat voor oplossing voor infusie
      – SmPC PADCEV™ poeder voor concentraat voor oplossing voor infusie

    Additioneel risicominimalisatie materiaal
    Patiënteninformatiepakket
     
  • XOSPATA™
      – Bijsluiter XOSPATA™ filmomhulde tabletten
      – SmPC XOSPATA™ filmomhulde tabletten

    Additioneel risicominimalisatie materiaal
    Waarschuwingskaart voor de patiënt
    Voorlichtingsbrochure voor voorschrijvers
     
  • XTANDI™
      – Bijsluiter XTANDI™
      – SmPC XTANDI™
     

Urologie

  • BETMIGA™
      – Bijsluiter BETMIGA™
      – SmPC BETMIGA™
     
  • VESICARE™
      – Bijsluiter VESICARE™ 5 & 10mg
      – SmPC VESICARE™ 5 & 10mg
     
  • VESOMNI™
      – Bijsluiter VESOMNI™
      – SmPC VESOMNI™


Nefrologie

  • EVRENZO™
      – Bijsluiter EVRENZO™
      – SmPC EVRENZO™

 

 

NON_2021_0057_NL_DEC

  • Linkedin
  • Twitter
LogoSolgan

Follow us on social media

linkedin_icon twitter_icon

Bottom footer menu

  • SITE MAP
  • PRIVACY STATEMENT
  • TERMS OF USE
  • CONTACT US
  • COOKIE BELEID
  • MODERN SLAVERY ACT
© 2020-2022 Astellas Pharma B.V.

Update de cookievoorkeur